Suzetrigine-enhanced MultimOdal Opioid-sparing THerapy in Cardiac and Bariatric SURGery

ID#: NCT07539623

Age: 18 - 85 years

Gender: All

Healthy Subjects: No

Study Phase: Phase 3

Recruitment Status: Recruiting

Start Date: May 01, 2026

End Date: December 22, 2026

Contact Information:
Himani Bhatt, DO
212-523-2500
Michael Lazar, MD
212-523-2500
Summary: This is prospective, randomized study. The purpose of this study is to evaluate whether the addition of Suzetrigine to well established multimodal pain regimen for participants undergoing bariatric patients undergoing weight-loss surgery and cardiac patients undergoing sternotomy will reduce post-operative opioid consumption and pain scores.
Eligibility:

Inclusion Criteria: To be eligible to participate in this study, an individual must meet all of the following criteria:

- Adults 18-85 years old

- Scheduled to undergo cardiac procedures via sternotomy or bariatric surgery (laparoscopic or open)

- All genders

Exclusion Criteria: Any individual who meets any of the following criteria will be excluded from participation in this study:

- ASA Class V

- Urgent or emergent surgery

- Contraindications to administration of Suzetrigine (e.g. concomitant use of strong CYP3A inhibitors)

- History of substance use disorder or chronic opioid use

- Reoperation

- Patient refusal or inability to consent

- Patients who take moderate-to-severe CYP3A inhibitors (such as Ritonavir, Voriconazole, and

- Clarithromycin)

- Patients who take moderate-to-severe CYP3A inducers (such as Phenytoin, Carbamazapine, and Rifabutin)
Find a Clinical Trial Find Cancer Clinical Trials